NCT05481411View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 13, 2022

Primary Completion Date

April 5, 2023

Study Completion Date

May 31, 2023

Conditions
Hepatic Impairment
Interventions
DRUG

Olpasiran

Subcutaneous injection

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

78215

The Texas Liver Institute, Inc., San Antonio

92377

Inland Empire Clinical Trials, LLC, Rialto

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT05481411 - A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment | Biotech Hunter | Biotech Hunter